Amongst genes uniquely down-regulated by CBPD-409 versus reader bromodomain inhibitors, we identified NKX3–1, CITED2, and CCND1 that are known for their driver roles in prostate cancer progression42–44 (Figures 5A and S6D). The gene discussed is CITED2; the disease is prostate carcinoma.